Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Danish pharma major Novo Nordisk has announced the launch of Ozempic (injectable semaglutide) in India. The popular ...

The managing director of Novo Nordisk India on Ozempic’s delayed launch in India, leading the fight against diabetes and ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Fondazione Telethon ETS' Waskyra has become the first gene therapy in the US for patients with Wiskott-Aldrich syndrome (WAS) ...

For Elizabeth Honigsberg, a general and bariatric surgeon and obesity and weight management specialist at Dartmouth Hitchcock Medical Center in Lebanon, combating obesity and the misconceptions that s ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...

Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and ...

A new study reveals that diabetes and weight loss drugs known as GLP-1s are lined with an increased risk of a chronic ...